PerSeptive and BioSepra agree patent dispute:
This article was originally published in Clinica
PerSeptive Biosystems' three-year legal battle with BioSepra and Sepracor has been settled out of court, with PerSeptive getting an unspecified sum and BioSepra gaining a non-exclusive licence to sell its HyperD product using PerSeptive's perfusion chromatography patents. PerSeptive is continuing its patent infringement action against Pharmacia Biotech, seeking punitive damages.
You may also be interested in...
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.